Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
Abstract Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown significant utility in the treatment of multiple hematological malignancies and solid tumors, including chronic myelo...
Main Authors: | Sunitha Shyam Sunder, Umesh C. Sharma, Saraswati Pokharel |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-07-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-023-01469-6 |
Similar Items
-
Echocardiographic and Cardiac MRI Comparison of Longitudinal Strain and Strain Rate in Cancer Patients Treated with Immune Checkpoint Inhibitors
by: Jibran Mirza, et al.
Published: (2022-08-01) -
ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
by: D. D. SAKAEVA
Published: (2017-06-01) -
Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Kota Yoshifuji, et al.
Published: (2022-10-01) -
A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor
by: Takashi Sawada, et al.
Published: (2024-03-01) -
Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
by: Jiangnan Liu, et al.
Published: (2024-03-01)